Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zannetti

Showing results (191-200 of 264) with videos related to

Pageof 27
Sort By:
European Journal of Nuclear Medicine|April 17, 2001
Bone marrow uptake of 99mTc-MIBI in patients with multiple myelomaR Fonti, S Del Vecchio, A Zannetti, et al.
Pharmaceutics|October 27, 2022
Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer CellsSimona Camorani, Silvia Tortorella, Lisa Agnello, et al.
Annals of Hematology|July 19, 2013
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomesLucia Pantani, Elena Zamagni, Beatrice Anna Zannetti, et al.
Expert Review of Hematology|December 5, 2015
Current and emerging triplet combination therapies for relapsed and refractory multiple myelomaL Pantani, A Brioli, P Tacchetti, et al.
Theranostics|September 16, 2017
Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ AptamerSimona Camorani, Billy Samuel Hill, Raffaela Fontanella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3Antonella Zannetti, Francesca Iommelli, Rosa Fonti, et al.
The Journal of Biological Chemistry|August 19, 2007
A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cellsPatrizia Caposio, Francesca Gugliesi, Claudia Zannetti, et al.
Bone Marrow Transplantation|January 11, 2012
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition diseaseA Brioli, E Zamagni, S Pasquali, et al.
Cell Communication and Signaling : CCS|February 10, 2025
A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signalingYlenia Ferrara, Debora Latino, Angela Costagliola di Polidoro, et al.
Thyroid : Official Journal of the American Thyroid Association|February 5, 2016
High-Frequency Ultrasound-Guided Injection for the Generation of a Novel Orthotopic Mouse Model of Human Thyroid CarcinomaAdelaide Greco, Sandra Albanese, Luigi Auletta, et al.
Pageof 27

Showing results (191-200 of 264) with videos related to

Sort By:
Pageof 27
European Journal of Nuclear Medicine|April 17, 2001
Bone marrow uptake of 99mTc-MIBI in patients with multiple myelomaR Fonti, S Del Vecchio, A Zannetti, et al.
Pharmaceutics|October 27, 2022
Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer CellsSimona Camorani, Silvia Tortorella, Lisa Agnello, et al.
Annals of Hematology|July 19, 2013
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomesLucia Pantani, Elena Zamagni, Beatrice Anna Zannetti, et al.
Expert Review of Hematology|December 5, 2015
Current and emerging triplet combination therapies for relapsed and refractory multiple myelomaL Pantani, A Brioli, P Tacchetti, et al.
Theranostics|September 16, 2017
Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ AptamerSimona Camorani, Billy Samuel Hill, Raffaela Fontanella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3Antonella Zannetti, Francesca Iommelli, Rosa Fonti, et al.
The Journal of Biological Chemistry|August 19, 2007
A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cellsPatrizia Caposio, Francesca Gugliesi, Claudia Zannetti, et al.
Bone Marrow Transplantation|January 11, 2012
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition diseaseA Brioli, E Zamagni, S Pasquali, et al.
Cell Communication and Signaling : CCS|February 10, 2025
A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signalingYlenia Ferrara, Debora Latino, Angela Costagliola di Polidoro, et al.
Thyroid : Official Journal of the American Thyroid Association|February 5, 2016
High-Frequency Ultrasound-Guided Injection for the Generation of a Novel Orthotopic Mouse Model of Human Thyroid CarcinomaAdelaide Greco, Sandra Albanese, Luigi Auletta, et al.
Pageof 27